Pair of Lancet stud­ies give fi­nal word on a promis­ing Sh­iono­gi an­tibi­ot­ic that turned out to be 'as good' as the oth­er 'sub­op­ti­mal' op­tions

Last Oc­to­ber, the FDA OK’d a se­mi-con­tro­ver­sial new an­tibi­ot­ic from Sh­iono­gi.

In one of two large stud­ies for the drug, known chem­i­cal­ly as ce­fide­ro­col …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.